Literature DB >> 16356525

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.

Gary P Kobinger1, Heinz Feldmann, Yan Zhi, Gregory Schumer, Guangping Gao, Friederike Feldmann, Steven Jones, James M Wilson.   

Abstract

This study evaluated the use of a chimpanzee-based adenovirus vaccine in mouse and Guinea pigs models of Zaire Ebola virus (ZEBOV) infection. Vaccine vector expressing the envelope glycoprotein of ZEBOV was created from the molecular clone of chimpanzee adenovirus pan7 (AdC7). AdC7 vaccine stimulated robust T and B cell responses to ZEBOV in naïve mice inducing complete protection to an otherwise lethal challenge of ZEBOV. Complete protection to Zaire Ebola virus was also observed in Guinea pigs vaccinated with a relatively low dose of AdC7 (5 x 10(9)/kg). Pre-existing immunity to AdHu5 was generated in mice following pre-exposure to AdHu5 or administration of pooled human immune globulin. Pre-existing immunity to human adenoviruses severely compromised the efficacy of the human AdHu5 vaccine but not the chimpanzee AdC7 vaccine. These results validate further development of Chimpanzee-based vaccine and highlight the impact of pre-existing immunity to the vaccine carrier.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356525     DOI: 10.1016/j.virol.2005.10.042

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  58 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

Review 2.  Clinical development of Ebola vaccines.

Authors:  Saranya Sridhar
Journal:  Ther Adv Vaccines       Date:  2015-09

3.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

4.  Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing.

Authors:  Nia Tatsis; Shih-Wen Lin; Kimberly Harris-McCoy; David A Garber; Mark B Feinberg; Hildegund C J Ertl
Journal:  Virology       Date:  2007-06-27       Impact factor: 3.616

Review 5.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

6.  Ebola: history, treatment, and lessons from a new emerging pathogen.

Authors:  Kevin S Harrod
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-12       Impact factor: 5.464

Review 7.  Ebola Vaccine: How Far are we?

Authors:  Rajani Sharma; Ketki Jangid
Journal:  J Clin Diagn Res       Date:  2017-05-01

8.  Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer.

Authors:  Natalya Belousova; Galina Mikheeva; Juri Gelovani; Victor Krasnykh
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

9.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

10.  Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

Authors:  Jason S Richardson; Michel K Yao; Kaylie N Tran; Maria A Croyle; James E Strong; Heinz Feldmann; Gary P Kobinger
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.